Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 9/2014

01-09-2014 | Research Article

MiR-186 targets ROCK1 to suppress the growth and metastasis of NSCLC cells

Authors: Guanghui Cui, Mingwei Cui, Yuhang Li, Youguang Liang, Weihao Li, Haizhou Guo, Song Zhao

Published in: Tumor Biology | Issue 9/2014

Login to get access

Abstract

MicroRNAs (miRNAs) act as oncogenes or tumor suppressors in human cancers. Increasing evidence shows that deregulation of miRNAs contributes to the development and progression of human non-small cell lung cancer (NSCLC). Here, we identified miR-186 as a tumor suppressor in NSCLC, which was decreased in NSCLC. Overexpression of miR-186 significantly inhibited proliferation, migration, and invasion of NSCLC cells. In addition, Rho-associated protein kinase 1 (ROCK1) was identified as a target of miR-186 in NSCLC cells. Restoration of ROCK1 remarkably reversed the tumor-suppressive effects of miR-186 on cell proliferation, migration, and invasion in NSCLC cells. Furthermore, ROCK1 was inversely correlated with miR-186 expression in NSCLC. Collectively, our data indicate that miR-186 functions as tumor suppressor in NSCLC by targeting ROCK1.
Literature
1.
2.
Gao D, Vahdat LT, Wong S, Chang JC, Mittal V. Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res. 2012;72:4883–9.PubMedCentralCrossRefPubMed
3.
4.
5.
Ke Y, Zhao W, Xiong J, Cao R. Downregulation of miR-16 promotes growth and motility by targeting HDGF in non-small cell lung cancer cells. FEBS Lett. 2013;587:3153–7.CrossRefPubMed
6.
Jiang L, He D, Yang D, Chen Z, Pan Q, Mao A, et al. Mir-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway. FEBS Lett. 2014;588:2009–15.CrossRefPubMed
7.
Wang X, Yu H, Lu X, Zhang P, Wang M, Hu Y. MiR-22 suppresses the proliferation and invasion of gastric cancer cells by inhibiting CD151. Biochem Biophys Res Commun. 2014;445:175–9.CrossRefPubMed
8.
Zhang N, Wei X, Xu L. Mir-150 promotes the proliferation of lung cancer cells by targeting p53. FEBS Lett. 2013;587:2346–51.CrossRefPubMed
9.
Guo H, Li Q, Li W, Zheng T, Zhao S, Liu Z. Mir-96 downregulates reck to promote growth and motility of non-small cell lung cancer cells. Mol Cell Biochem. 2014;390:155–60.CrossRefPubMed
10.
Wan L, Zhang L, Fan K, Wang J. MiR-27b targets LIMK1 to inhibit growth and invasion of NSCLC cells. Mol Cell Biochem. 2014;390:85–91.CrossRefPubMed
11.
Cai J, Wu J, Zhang H, Fang L, Huang Y, Yang Y, et al. MiR-186 downregulation correlates with poor survival in lung adenocarcinoma, where it interferes with cell-cycle regulation. Cancer Res. 2013;73:756–66.CrossRefPubMed
12.
Li H, Yin C, Zhang B, Sun Y, Shi L, Liu N, et al. PTTG1 promotes migration and invasion of human non-small cell lung cancer cells and is modulated by miR-186. Carcinogenesis. 2013;34:2145–55.CrossRefPubMed
13.
Wang XC, Tian LL, Jiang XY, Wang YY, Li DG, She Y, et al. The expression and function of miRNA-451 in non-small cell lung cancer. Cancer Lett. 2011;311:203–9.CrossRefPubMed
14.
Xiong S, Zheng Y, Jiang P, Liu R, Liu X, Chu Y. MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. Int J Biol Sci. 2011;7:805–14.PubMedCentralCrossRefPubMed
15.
Kumarswamy R, Mudduluru G, Ceppi P, Muppala S, Kozlowski M, Niklinski J, et al. MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer. 2012;130:2044–53.CrossRefPubMed
16.
Ferrer G, Navarro A, Hodgson K, Aymerich M, Pereira A, Baumann T, et al. MicroRNA expression in chronic lymphocytic leukemia developing autoimmune hemolytic anemia. Leuk Lymphoma. 2013;54:2016–22.CrossRefPubMed
17.
Wen X, Ding L, Wang JJ, Qi M, Hammonds J, Chu H, et al. ROCK1 and LIM kinase modulate retrovirus particle release and cell-cell transmission events. J Virol. 2014;88:6906–21.PubMedCentralCrossRefPubMed
18.
Xu X, Li S, Lin Y, Chen H, Hu Z, Mao Y, et al. MicroRNA-124-3p inhibits cell migration and invasion in bladder cancer cells by targeting ROCK1. J Transl Med. 2013;11:276.PubMedCentralCrossRefPubMed
19.
Zhang C, Zhang S, Zhang Z, He J, Xu Y, Liu S. Rock has a crucial role in regulating prostate tumor growth through interaction with c-Myc. Oncogene. 2013
20.
21.
Li J, Song Y, Wang Y, Luo J, Yu W. MicroRNA-148a suppresses epithelial-to-mesenchymal transition by targeting ROCK1 in non-small cell lung cancer cells. Mol Cell Biochem. 2013;380:277–82.CrossRefPubMed
22.
Zheng B, Liang L, Wang C, Huang S, Cao X, Zha R, et al. MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17:7574–83.CrossRef
23.
Wan X, Cheng Q, Peng R, Ma Z, Chen Z, Cao Y, et al. ROCK1, a novel target of miR-145, promotes glioma cell invasion. Mol Med Rep. 2014;9:1877–82.PubMed
Metadata
Title
MiR-186 targets ROCK1 to suppress the growth and metastasis of NSCLC cells
Authors
Guanghui Cui
Mingwei Cui
Yuhang Li
Youguang Liang
Weihao Li
Haizhou Guo
Song Zhao
Publication date
01-09-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2168-6

Other articles of this Issue 9/2014

Tumor Biology 9/2014 Go to the issue

Research Article

miR-195 Targets HDGF to inhibit proliferation and invasion of NSCLC cells

Research Article

Anti-tumor activity of oridonin on SNU-5 subcutaneous xenograft model via regulation of c-Met pathway

Research Article

Correlations of common polymorphism of EVI-1 gene targeted by miRNA-206/133b with the pathogenesis of breast cancer

Research Article

MicroRNA-520a-5p displays a therapeutic effect upon chronic myelogenous leukemia cells by targeting STAT3 and enhances the anticarcinogenic role of capsaicin

Research Commentary

Letter regarding Chen et al. entitled “A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma”

Research Article

The diagnostic value of serum hybrid capture 2 (CH2) HPV DNA in cervical cancer: a systematic review and meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits